Cardiac Imaging
CCTA for CAD diagnosis and risk stratification
Also called CCTA, coronary CTA, CT coronary angiography
Sources: 12 new papers · 5 key papers · updated Oct 20, 2026
“This is an important trial looking at a group that we see a lot in clinical practice. We know historically that this group has increased residual risk when they're optimized on lifestyle, which is [where] we first start with triglyceride lowering. We optimize their lipids,…”
Expert labels are toward ESSENCE-TIMI 73b's result, from named public quotes (n=1). As of Oct 8, 2026.
Unverified · drafted by AI from the sources cited below
Coronary computed tomography angiography (CTA) is a non-invasive imaging method that uses a CT scanner and contrast material to capture detailed images of the coronary vessels, which are the veins and arteries of the heart.12 CTA has experienced significant technological improvements over the last 2 decades and is used to detect significant coronary stenosis as a substitute for conventional invasive coronary angiography in patients with suspected coronary artery disease.3 Additionally, computed tomography coronary anatomy with functionality assessment has the potential to become a first line in diagnosis.3
CTA has shown high accuracy in detecting significant coronary stenosis and can serve as a substitute for conventional invasive coronary angiography in patients with suspected coronary artery disease.1 In patients with coronary stenosis, CTA-derived physiological assessment serves as a surrogate for intracoronary pressure and velocity wires.1 Noninvasive imaging assessment of plaque burden and morphology is becoming a valuable substitute for intravascular imaging, and assessments of wall shear stress and perivascular inflammation have recently been introduced to support risk management.1 Furthermore, elevated lipoprotein(a) and coronary artery calcium scores are individually associated with increased atherosclerotic cardiovascular disease risk.2 Parallel improvements in coronary imaging modalities can assess plaque volumes and composition using noninvasive techniques.3
CTA renders possible decision-making about revascularization solely based on computed tomography.1 Complete CTA assessment could provide a 1-stop-shop for diagnosis, risk management, and decision-making on treatment.1 Many studies have longitudinally assessed changes in plaque characteristics in response to various treatments, aiming to demonstrate plaque regression and improvements in high-risk features.2 Furthermore, angiography remains the most widely used method to guide percutaneous coronary intervention (PCI), as studied in FAVOR III China, which assessed clinical outcomes using the quantitative flow ratio for PCI selection.3
15 O‐water PET‐detected myocardial ischaemia and CT‐derived FFR: Predicting the functional significance of anatomical stenosis
Clinical Physiology and Functional Imaging — J V — Oct 2026
Sessions from public communities on Synapse. RSVP to join the live discussion.
Angiographic quantitative flow ratio-guided coronary intervention (FAVOR III China): a multicentre, randomised, sham-controlled trial
The Lancet
429 citations · 2021 · among the most cited on Coronary CT angiography
Coronary Computed Tomographic Angiography for Complete Assessment of Coronary Artery Disease
Journal of the American College of Cardiology — Serruys P
208 citations · 2021 · among the most cited on Coronary CT angiography
Coronary Atherosclerotic Plaque Regression
Journal of the American College of Cardiology — Dawson L
197 citations · 2022 · among the most cited on Coronary CT angiography
Eruptive Calcified Nodules as a Potential Mechanism of Acute Coronary Thrombosis and Sudden Death
Journal of the American College of Cardiology — Torii S
180 citations · 2021 · among the most cited on Coronary CT angiography
A clinical question appears here only when its condition matches this topic, an outcome and a comparator were extracted from the studies, at least two studies and a patient count are on file, and the certainty is low or higher.
Supports benefit, no benefit shown, and mixed describe the direction of the measured effect. No benefit shown means the evidence does not support a benefit. It is not a finding of harm. Too little evidence means the question did not clear that bar.
Study count, RCT count, and patient count are separate. The patient total adds only studies that are linked into a study family and whose sample size is not flagged as implausible. A reversal is listed only when at least one randomized trial sits on each side of the change.
The overview is drafted from the guideline recommendations, trials, papers, and questions on this page, and every sentence has to cite one of them. It stays unverified until an NPI-verified clinician or a Synapse admin approves it. Approving records that person's name.
Medicine — Jiang W — Oct 2026
Independent Association of Lipoprotein(a) and Coronary Artery Calcification With Atherosclerotic Cardiovascular Risk
Journal of the American College of Cardiology — Mehta A
180 citations · 2022 · among the most cited on Coronary CT angiography